Allogene Therapeutics, Inc. is a pharmaceutical company based in the United States with a focus on immuno-oncology. Specializing in developing genetically engineered allogeneic T-cell products for cancer and autoimmune diseases, the company aims to redefine CAR T therapy. Their innovative approach, using off-the-shelf T-cell candidates from healthy donors, allows for broader patient eligibility and scalability. With a Risk Rating Score of 25.2, Allogene Therapeutics is considered to be of medium risk. The company generates revenue primarily from collaborations and licensing agreements to support their research and development efforts.